Compare
InMed Pharmaceuticals Inc. vs Alaunos Therapeutics, Inc. vs Avenue Therapeutics, Inc. vs Procyon Corp
| Latest fiscal year | InMed Pharmaceuticals Inc. INM | Alaunos Therapeutics, Inc. TCRT | Avenue Therapeutics, Inc. ATXI | Procyon Corp PCYNLast annual report: year ended 2024-06-30 |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2024-06-30 |
| Revenue | n/a | $5.0K | $1.40M | $4.98M |
| Revenue growth (YoY) | n/a | -50.0% | n/a | +6.4% |
| Gross margin | n/a | n/a | n/a | 78.1% |
| Operating margin | n/a | n/m | -219.6% | -4.6% |
| Net margin | n/a | n/m | -207.2% | -6.8% |
| Net income | -$12.56M | -$4.18M | -$2.91M | -$341.1K |
| EPS (Diluted) | -$3.12 | -$2.20 | n/a | -$0.04 |
| Operating cash flow | -$8.64M | -$2.87M | -$1.83M | -$61.3K |
| Free cash flow | n/a | -$2.97M | n/a | -$125.2K |
| Cash & equivalents | n/a | $1.39M | $2.85M | n/a |
| Total assets | $3.03M | $2.97M | $2.93M | $3.20M |
| Total liabilities | $1.96M | $813.0K | $1.10M | $917.1K |
| Shareholders' equity | $1.08M | $2.15M | $1.83M | $2.29M |
| Return on year-end equity | n/m | -194.0% | -158.8% | -14.9% |
| Shares outstanding | 5.34M | 2.35M | 3.18M | 8.12M |
Revenue, most recent five fiscal years
| Fiscal year | InMed Pharmaceuticals Inc. | Alaunos Therapeutics, Inc. | Avenue Therapeutics, Inc. | Procyon Corp |
|---|---|---|---|---|
| Latest | $4.94M Ended 2025-06-30 | $5.0K Ended 2025-12-31 | $1.40M Ended 2025-12-31 | $4.98M Ended 2024-06-30 |
| 1 year earlier | $4.60M Ended 2024-06-30 | $10.0K Ended 2024-12-31 | $0 Ended 2024-12-31 | $4.69M Ended 2023-06-30 |
| 2 years earlier | $4.14M Ended 2023-06-30 | $5.0K Ended 2023-12-31 | n/a | $4.84M Ended 2022-06-30 |
| 3 years earlier | $1.09M Ended 2022-06-30 | $2.92M Ended 2022-12-31 | n/a | $4.72M Ended 2021-06-30 |
| 4 years earlier | n/a | $398.0K Ended 2021-12-31 | n/a | $4.33M Ended 2020-06-30 |